Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndrome

28 Sept 2011

Abstract excerpt

Abstract A phase II non‐randomized single arm trial of oral panobinostat (LBH589) was conducted in patients with low or intermediate‐1 risk myelodysplastic syndrome (MDS). The objective of this study was to determine the clinical efficacy, safety, and tolerability of panobinostat in this patient population. The study would stop early if there was a chance >99% that the average overall response rate was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Gestational Trophoblastic Disease Studies
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22072492
DOI: 10.1002/ajh.22198

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate‐1 risk myelodysplastic syndromePMID 22072492Read ↗

Current therapeutic approaches for patients with myelodysplastic syndromes.Semantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.Semantic proximity Read ↗

Lowering the boom on lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selectionSemantic proximity Read ↗

A Phase I Study of MLN4924 and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeSemantic proximity Read ↗

A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid LeukemiaSemantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaSemantic proximity Read ↗

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?Semantic proximity Read ↗

Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Semantic proximity Read ↗

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMTSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.